Pfizer’s one-time haemophilia B therapy Beqvez granted FDA approval
Pfizer’s Beqvez (fidanacogene elaparvovec-dzkt) has been approved by the US Food and Drug Administration (FDA) to treat adults with moderate-to-severe haemophilia B. The regulator has specifically authorised the one-time therapy for use in patients who …